Cognoa; Olympus’s endoscope; BioSticker

Published by Daniel at September 1, 2022

Cognoa aims to rule out or diagnose ASD. Olympus's endoscope spots suspicious lesions and polyps. The BioSticker prevent illness exacerbation...

Olympus to roll out colonoscopy AI for spotting lesions and polyps in real-time

Olympus has received FDA approval for its new endoscope, The ENDO-AID program, an artificial intelligence platform designed to identify red flags, lesions, and polyps during a colonoscopy. The AI’s platform emphasizes specific areas whenever a lesion appears on the video screen, including potential malignant lesions and benign tumors. Furthermore, the company plans to extend this technology’s use to screening for lesions in additional areas such as the esophagus, stomach, and other gastrointestinal organs.

Olympus has also gained FDA clearances for two colonoscopes. One is a short-bending, high-definition scope used to classify colorectal polyps. The other allows visualization of the intestine’s mucus membranes with a 170-degree field of view. Moreover, Olympus automatically notifies a separate and compatible device that cleans the endoscopes after use with a combination of ultrasonic waves and detergents.(1)

Cognoa's AI-powered diagnostic app for autism clears clinical study, heads for FDA review.

There is a significant need for early Autism Spectrum Disorder diagnosis in pediatric primary care as this disorder can affect a child’s neurodevelopment and interaction with society. Therefore, the FDA has cleared Cognoa’s AI- a diagnostic app that can identify signs of autism, allowing early interventions during critical windows in a child’s development.

The mobile app gathers information from parents, caregivers, and healthcare providers through questionnaires and can send a video of children interacting with others before supplying the result as a diagnostic aid to the medical practitioner. Additionally, Cognoa’s recently completed a clinical trial of 425 children evaluating the diagnostic app to the clinical standards accomplished by specialists based on DSM-5 criteria that showed promising results.(2)

BioSticker FDA Cleared for Month-Long Vitals Monitoring

BioIntelliSense company won FDA clearance for its BioSticker. This single-use wearable sensor can measure respiratory rate, heart rate, body temperature, sleep status, gait analysis, and fall detection. All this information can be recorded continuously for thirty days, providing healthcare workers with necessary information regarding patients’ diseases and conditions.

The device can allow physicians to monitor a patient’s vital signs in their home and identify when they may have exacerbated illness even before they manifest symptoms, reducing emergency department visits, hospitalizations, and hospital stays.(3)